Ginkgo Bioworks Secures $4.66M Contract to Enhance Microbial Research at EMSL with Automated Platform

Reuters
07-30
<a href="https://laohu8.com/S/DNA.WS">Ginkgo Bioworks</a> Secures $4.66M Contract to Enhance Microbial Research at EMSL with Automated Platform

Ginkgo Bioworks Holdings Inc., a leader in cell programming and biosecurity, has been awarded a $4.66 million contract to deliver an advanced automated anaerobic phenotyping platform to the Environmental Molecular Sciences Laboratory (EMSL) at Pacific Northwest National Laboratory. This system, based on Ginkgo's Reconfigurable Automation Cart $(RAC)$ technology, will consist of an integrated workcell with 18 devices housed within a modular anaerobic chamber. The platform will enable EMSL scientists to conduct complex end-to-end anaerobic phenotyping workflows remotely, enhancing research efficiency and accelerating discoveries in microbial engineering and bioeconomy science. This collaboration aims to strengthen U.S. leadership in biotechnology and bioeconomy research.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ginkgo Bioworks Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE40506) on July 30, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10